[Suppression of conjunctival provocation by 0.1% pemirolast potassium ophthalmic solution in VKC].
Nakagawa
Y
Y
Department of Ophthalmology, Osaka University School of Medicine.
Jikuhara
Y
Y
Higasida
M
M
Yuasa
T
T
D000293:Adolescent; D000328:Adult; D000941:Antigens / Q000276:immunology; D003228:Conjunctiva / Q000187:drug effects* / Q000276:immunology; D003233:Conjunctivitis, Allergic / Q000276:immunology*; D005260:Female; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D008297:Male; D009883:Ophthalmic Solutions; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000494:pharmacology*
D000941:Antigens; D006633:Histamine Antagonists; D009883:Ophthalmic Solutions; D011725:Pyridines; D011744:Pyrimidinones; C055139:pemirolast